menu
    • menu
    [{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Moffitt Cancer Center \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Ronald Buckanovich","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Ronald Buckanovich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ronald Buckanovich \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Ronald Buckanovich \/ Genentech"},{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stamford Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stamford Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Vismodegib

    Menu

    Vismodegib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stamford Pharmaceuticals

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Stamford Pharmaceuticals

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-002,Vismodegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study

                            Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : SP-002,Vismodegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Moffitt Cancer Center

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Moffitt Cancer Center

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

                            Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Basal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Hospital, Lille

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            University Hospital, Lille

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

                            Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 30, 2022

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ronald Buckanovich

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Ronald Buckanovich

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Ca...

                            Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fallopian Tube Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Vismodegib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth